Nivolumab Plus Relatlimab Is Safe and Efficacious in Pretreated Melanoma

Skip to Main Content

Skip Nav Destination

Article navigation

Research Watch| February 24 2023

Online Issn: 2159-8290

Print Issn: 2159-8274

2023

American Association for Cancer Research

Cancer Discov OF1.

https://doi.org/10.1158/2159-8290.CD-RW2023-032

Abstract

Nivolumab plus relatlimab has a manageable safety profile in patients with advanced pretreated melanoma.

2023

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.